(+)-DOI | 99665-04-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+)-DOI
• 英文别名: (S)-(+)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane；Benzeneethanamine, 4-iodo-2,5-dimethoxy-alpha-methyl-, (alphaS)-；(2S)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine
• CAS: 99665-04-0
• 化学式: C₁₁H₁₆INO₂
• 分子量: 321.158
• InChiKey: BGMZUEKZENQUJY-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+)-DOI 、 盐酸 以80%的产率得到
  参考文献：
  名称：

  MATHIS, C. A.;HOFFMAN, A. J.;NICHOLS, D. E.;SHULGIN, A. T., J. LABELL. COMPOUNDS AND RADIOPHARM., 25,(1988) N 11, C. 1255-1265

  摘要：

  DOI：
• 作为产物：
  描述：

  4-碘-2,5-二甲氧基-α-甲基苯甲胺 生成 (+)-DOI
  参考文献：
  名称：

  5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogs

  摘要：

  1-(2,5-Dimethoxy-4-bromophenyl)-2-aminopropane (DOB; 1a) is a purported serotonin (5-HT) agonist that binds selectively to central 5-HT2 binding sites. Systematic removal of any or all of the aromatic substituents had relatively little effect on 5-HT1 binding but reduced 5-HT2 binding by approximately 2 or more orders of magnitude. Demethylation of the 2-methoxy group of 1a, or introduction of an N-n-propyl group, doubled 5-HT1-site affinity but decreased 5-HT2-site affinity by 3- and 30-fold, respectively. In tests of stimulus generalization, using rats trained to discriminate DOM from saline, the 2-demethyl and N-propyl derivatives were found to produce stimulus effects similar to those of DOB. In addition, the S-(+) isomer of the iodo analogue of 1a was found to possess one-third the affinity of its R-(-) enantiomer at 5-HT2 sites and also resulted in DOM-stimulus generalization. Of the DOB analogues examined, DOB (1a) possesses optimal selectivity for 5-HT2 binding.

  DOI：

  10.1021/jm00152a005

文献信息

• [EN] CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON S DISEASE<br/>[FR] PROMÉDICAMENTS DE CARBAMATE DE CATÉCHOLAMINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：H LUNDBECK AS

  公开号：WO2020234277A1

  公开（公告）日：2020-11-26

  The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

  本发明提供了化合物的公式（Id），这些化合物是儿茶酚胺的前药，用于治疗神经退行性疾病和紊乱。本发明还提供了包括本发明化合物的药物组合物，以及使用本发明化合物治疗神经退行性或神经精神疾病和紊乱的方法，特别是帕金森病。
• [EN] NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE<br/>[FR] NOUVEAUX PROMÉDICAMENTS DE CATÉCHOLAMINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：H LUNDBECK AS

  公开号：WO2019101917A1

  公开（公告）日：2019-05-31

  The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease. Accordingly, the present invention relates to compounds of formula (Id) wherein R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or R1 and R2 are both represented by substituent (i) below; or R1 and R2 are both represented by substituent (ii) below; or R1 is substituent (i) and R2 is substituent (ii); or R1 is substituent (ii) and R2 is substituent (i); (i) (ii) wherein * indicates the attachment point; and wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.

  本发明提供了化合物(I)的中间体，用于治疗神经退行性疾病和紊乱。本发明还提供了包括本发明化合物的药物组合物，以及使用本发明化合物治疗神经退行性或神经精神疾病和紊乱的方法，特别是帕金森病。因此，本发明涉及化合物(I d)的公式，其中R1为H，R2从下面的取代基(i)和(ii)中选择一个；或R1从下面的取代基(i)和(ii)中选择一个，R2为H；或R1和R2都由下面的取代基(i)表示；或R1和R2都由下面的取代基(ii)表示；或R1为取代基(i)，R2为取代基(ii)；或R1为取代基(ii)，R2为取代基(i)；(i) (ii) 其中*表示连接点；取代基(i)上连接点的碳原子处于S构型；或其药用可接受盐。
• [EN] NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASES<br/>[FR] NOUVEAUX PROMÉDICAMENTS DE CATÉCHOLAMINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES DE PARKINSON
  申请人：H LUNDBECK AS

  公开号：WO2020234275A1

  公开（公告）日：2020-11-26

  The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

  本发明提供了化合物（Id）的公式，这些化合物是儿茶酚胺的前药，用于治疗神经退行性疾病和紊乱。本发明还提供了包括本发明化合物的药物组合物以及使用本发明化合物治疗神经退行性或神经精神疾病和紊乱的方法，特别是帕金森病。
• Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders
  申请人：Yamashita Hiroshi

  公开号：US20090264404A1

  公开（公告）日：2009-10-22

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种杂环化合物或其盐，其化学式为（1）：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香族基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的谱，包括中枢神经系统障碍，无副作用且安全性高。
• PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS
  申请人：YAMASHITA Hiroshi

  公开号：US20110152286A1

  公开（公告）日：2011-06-23

  The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  本发明提供了一个由通式（1）所代表的杂环化合物：该化合物具有广泛的治疗精神障碍的光谱，包括中枢神经系统障碍，无副作用且安全性高。